Neoadjuvant Chemotherapy With Doxorubicin and Cisplatin in Malignant Fibrous Histiocytoma of Bone: A European Osteosarcoma Intergroup Study
Open accessThe DOI matches its Crossref record.
Abstract
PURPOSE: Studies involving small case series have suggested that malignant fibrous histiocytoma of bone (MFH-B) is a chemosensitive tumor and that chemotherapy may improve survival. In this study, we evaluated clinical and pathologic response rates and survival in a series of patients treated with a consistent chemotherapy regimen of doxorubicin and cisplatin (DOX/DDP). PATIENTS AND METHODS: Study patients were required to have biopsy-proven MFH-B, no previous chemotherapy, and primary or metastatic measurable disease and to be ≤ 65 years of age. Treatment consisted of doxorubicin 25 mg/m 2/d days 1 through 3 and cisplatin 100 mg/m 2 by 4-hour intravenous infusion every 3 weeks for six cycles. In patients with operable primary tumors, chemotherapy was planned to start within 42 days of biopsy, with definitive surgery performed after three cycles. RESULTS: Forty-one patients had operable nonmetastatic limb sarcomas, and 23 (56%) completed six chemotherapy cycles. Limb salvage was possible in 33 patients (80%), and 16 (42%) of 38 assessable specimens showed a good pathologic response (≥ 90% necrosis). Median time to progression was 56 months, and the 5-year progression-free survival rate was 56% (95% confidence interval [CI], 40% to 72%). Median survival time was 63 months, and the 5-year survival rate was 59% (95% CI, 41% to 77%). Patients with a good pathologic response had longer survival times and times to progression than did those with a poor response. Also treated were two patients with locally recurrent and nine with metastatic disease, and these patients had a median survival time of 17.5 months. CONCLUSION: Our study suggests that adjuvant or neoadjuvant chemotherapy with DOX/DDP is beneficial in MFH-B. Good pathologic response rates and survivals are quite comparable with those for osteosarcoma, a related bone tumor for which adjuvant or neoadjuvant chemotherapy is an accepted practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Casali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617
Self-citationStrauss, S. J., Frezza, A. M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., Bonvalot, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1995 · Cited by 513
Osteosarcoma, Chondrosarcoma, and Chordoma
Whelan, J. S., & Davis, L. E. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1743 · Cited by 479
Self-citationSkubitz, K. M., & D'Adamo, D. R. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1409 · Cited by 277
Osteosarcoma over the age of forty
Grimer, R. J., Cannon, S. R., Taminiau, A. M., Bielack, S., Kempf-Bielack, B., Windhager, R., Dominkus, M., Saeter, G., Bauer, H., Meller, I., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00478-1 · Cited by 188
“It is possible, however, to extrapolate the likely side-effects from papers detailing the use of similar chemotherapy regimes in patients up to the age of 60 years with MFH [5,21,22].”
BackgroundSelf-citation
Metadata
- Authors
- Bramwell, V. H. C., Steward, W. P., Nooij, M., Whelan, J., Craft, A. W., Grimer, R. J., Taminau, A. H. M., Cannon, S. R., Malcolm, A. J., Hogendoorn, P. C. W., Uscinska, B., Kirkpatrick, A. L., Machin, D., & Van Glabbeke, M. M.
- Venue
- Journal of Clinical Oncology
- Published
- 1999-10
- Volume
- 17
- Issue
- 10
- Pages
- 3260-3269
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106327881
- Cited by
- 93
- References
- 0
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neoadjuvant Chemotherapy With Doxorubicin and Cisplatin in Malignant Fibrous Histiocytoma of Bone: A European Osteosarcoma Intergroup Study. https://app.cochat.ai/papers/10.1200/jco.1999.17.10.3260
- The paper
- Bramwell, V. H. C., Steward, W. P., Nooij, M., Whelan, J., Craft, A. W., Grimer, R. J., Taminau, A. H. M., Cannon, S. R., Malcolm, A. J., Hogendoorn, P. C. W., Uscinska, B., Kirkpatrick, A. L., Machin, D., & Van Glabbeke, M. M. (1999). Neoadjuvant Chemotherapy With Doxorubicin and Cisplatin in Malignant Fibrous Histiocytoma of Bone: A European Osteosarcoma Intergroup Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1999.17.10.3260
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.